Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma-Reference-Cited by-同舟云学术

Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma

Published:2023-12-12 Issue:24 Volume:101 Page:
ISSN:0028-3878
Container-title:Neurology
language:en
Short-container-title:Neurology

Author:

Pepys Jack¹^ORCID,Stoff Ronen¹^ORCID,Ramon-Gonen Roni¹^ORCID,Ben-Betzalel Guy¹,Grynberg Shirly¹^ORCID,Frommer Ronnie Shapira¹^ORCID,Schachter Jacob¹^ORCID,Asher Nethanel¹^ORCID,Taliansky Alisa¹^ORCID,Nikitin Vera¹,Dori Amir¹^ORCID,Shelly Shahar¹

Affiliation:

1. From the Department of Biomedical Sciences (J.P.), Humanitas University, Milan, Italy; Ella Institute for Immuno-Oncology and Melanoma (R.S., G.B.-B., S.G., R.S.F., J.S., N.A.), Sheba Medical Center; Department of Neurology and Neurosurgery (R.S., G.B.-B., S.G., R.S.F., J.S., N.A., A.T., V.N., A.D.), Sackler Faculty of Medicine, Tel Aviv University; The Graduate School of Business Administration (R.R.-G.), Bar-Ilan University; Department of Neurology (A.T., V.N., A.D.), Sheba Medical Center, Ramat...

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Neurology (clinical)

Link

https://www.neurology.org/doi/pdfdirect/10.1212/WNL.0000000000207632

Reference50 articles.

1. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

2. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

3. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

4. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

5. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neurological Adverse Events Related to Immune Checkpoint Inhibitors: A Practical Review;Pharmaceuticals;2024-04-14

2. Neurological autoimmunity in melanoma patients: a comparison between those exposed and non-exposed to immune checkpoint inhibitors;Journal of Neurology;2024-03-11